Discover Lantern Pharma's transformative 2024 journey in precision oncology with AI breakthroughs, global trial expansions, and key clinical milestones ...
Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...
Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...
DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...
Detailed price information for Zentalis Pharmaceuticals Inc (ZNTL-Q) from The Globe and Mail including charting and trades.
Evolution in women's cancer diagnostics: from histopathology to molecular testing, personalized treatment for breast, ovarian ...
Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...
2d
Powered Drug DiscoveryVANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) ...
A real-world study reveals the need for increased homologous repair deficiency and BRCA1/2 testing in patients with ovarian ...
The new drug development corporation Daimbio announced on the 25th that it has completed a series A funding round worth 12 ...
In a recent MedPage Today video, Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake ...
PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback